A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia

Published:2016-07-22 Issue:10 Volume:91 Page:1020-1025
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Flinn Ian W.¹²,Ruppert Amy S.³,Harwin William¹⁴,Waterhouse David¹⁵,Papish Steven⁶,Jones Jeffrey A.³,Hainsworth John¹²,Byrd John C.³⁷

Affiliation:

1. Sarah Cannon Research Institute; Nashville Tennessee

2. Tennessee Oncology; Nashville Tennessee

3. Division of Hematology and Comprehensive Cancer Center at the Ohio State University; Columbus Ohio

4. Florida Cancer Specialists; Ft. Myers Florida

5. Oncology Hematology Care; Cincinnati Ohio

6. Hematology-Oncology Associates of Northern NJ; Morristown New Jersey

7. Division of Medicinal Chemistry; College of Pharmacy, The Ohio State University; Columbus Ohio

Funder

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Reference33 articles.

1. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines;Hallek;Blood,2008

2. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications;Campo;Blood,2011

3. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia;Dighiero;N Engl J Med,1998

4. Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials;CLL Trialists' Collaborative Group;J Natl Cancer Inst,1999

5. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenstrom's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies;Johnson;Hematol J,2004

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2024-01-04

2. Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials;Expert Opinion on Investigational Drugs;2020-05-27

3. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies;Journal of Geriatric Oncology;2020-01

4. Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach;Drugs & Aging;2019-05-04

5. Anti-CD20 monoclonal antibodies: reviewing a revolution;Human Vaccines & Immunotherapeutics;2018-09-06